Interleukin-17A (IL-17A): A silent amplifier of COVID-19

Francesco Maione; Gian Marco Casillo; Federica Raucci; Cristian Salvatore; Giovanna Ambrosini; Luisa Costa; Raffaele Scarpa; Francesco Caso; Mariarosaria Bucci

Biomedicine & Pharmacotherapy (Oct 2021)

Interleukin-17A (IL-17A): A silent amplifier of COVID-19

Francesco Maione,
Gian Marco Casillo,
Federica Raucci,
Cristian Salvatore,
Giovanna Ambrosini,
Luisa Costa,
Raffaele Scarpa,
Francesco Caso,
Mariarosaria Bucci

Affiliations

Francesco Maione: Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy
Gian Marco Casillo: Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy
Federica Raucci: Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy
Cristian Salvatore: New.Fa.DEm SRL, Viale Ferrovie Dello Stato, 1, 80014 Giugliano in Campania, Naples, Italy
Giovanna Ambrosini: New.Fa.DEm SRL, Viale Ferrovie Dello Stato, 1, 80014 Giugliano in Campania, Naples, Italy
Luisa Costa: Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy
Raffaele Scarpa: Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy
Francesco Caso: Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy; Corresponding authors.
Mariarosaria Bucci: Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy; Corresponding authors.

Journal volume & issue: Vol. 142
p. 111980

Abstract

Read online

One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this “unique” cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords